Connect your AI

TTRX TTRX Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Regeneron PharmaceuticalsREGN

$198.6M+10.6%

Bausch Health CompaniesBHC

$27M-41.3%

Journey Medical CorporationDERM

$88K+111%

Celldex TherapeuticsCLDX

-$6.28M-239%

Arcutis Biotherapeutics, Inc.ARQT

$11.73M+257%

Kymera TherapeuticsKYMR

$3.57M+228%

Other financials

Income statement

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Balance sheet

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Cash flow

Operating cash flow-$1.6M-448%

Valuation

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Returns & leverage

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Where this comes from

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about TTRX's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is TTRX's increase (decrease) in prepaid expense and other assets?: TTRX (TTRX) reported increase (decrease) in prepaid expense and other assets of $123.74K in Q1 2026.
What does increase (decrease) in prepaid expense and other assets mean?: This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.